Advances in Hematology / 2012 / Article / Tab 2

Review Article

Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia

Table 2

Selected clinical trials using lenalidomide in combination for treatment CLL. NR: not reported.

StudyRegimenNo. of patientsTLS all gradesTFR all gradesHematologic side effects grade 3/4OR (%)CR (%)OS (%)PFS

Ferrajoli et al. [22] phase II
relapsed/refractory CLL
10 mg/d Lenalidomide + rituximab weekly591,7%37%Neutropenia 68% thrombocytopenia 22% anemia 10%648NRNR

Badoux et al. [24] phase II
relapsed/refractory CLL
10 mg/d lenalidomide + ofatumumab weekly16NR13%Neutropenia 50%
anemia 13%
6313NRNR

Blum et al. [29] phase I
relapsed/refractory CLL
2.5 mg/d escalated to 25 mg/d lenalidomide + flavopiridol1514%7%Neutropenia 86% thrombocytopenia 38% anemia 38%460NRNR

GIMEMA LLC 606 [25] phase I
relapsed/refractory CLL
2.5 mg/d escalated to 15 mg/d lenalidomide + cyclophosphamide + fludarabine9 011%Transient grade 3-4 neutropenia in the majority of pts6733NRNR

Egle et al. [27] phase
untreated CLL
2.5 mg/d escalated to 25 mg/d lenalidomide + fludarabine + rituximab10 00Neutropenia 70%900NRNR

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.